BioCentury
ARTICLE | Clinical News

Novartis' secukinumab meets in Phase III psoriasis trial

March 25, 2014 12:17 AM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) said subcutaneous secukinumab ( AIN457) met the co-primary endpoints of improving PASI 75 and Investigator's Global Assessment (IGA) response rates at week 12 vs. placebo in both the double-blind, international Phase III JUNCTURE and Phase III FEATURE trials to treat moderate to severe plaque psoriasis. Secukinumab was delivered via an autoinjector in JUNCTURE, which enrolled 182 patients, and via pre-filled syringes in FEATURE, which enrolled 177 patients. Data from the trials were presented at the American Academy of Dermatology meeting in Denver. ...